Roche’s Enspryng Receives FDA Priority Review for MOGAD
Roche Receives FDA Priority Review for Enspryng in MOGAD Following Positive Phase 3 Results Roche announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a…
Read MoreRoche’s Enspryng Receives FDA Priority Review for MOGAD
Johnson & Johnson Highlights New Neuropsychiatry Data at Psych Congress 2026
Johnson & Johnson to Present 24 Neuropsychiatry Data Sets at Psych Congress 2026 Johnson & Johnson (NYSE: JNJ) will present 24 abstracts featuring clinical trial data and real-world evidence from…
Novo Nordisk STEP Young Data Show 40.4% of Children with Obesity Achieved BMI Below Obesity Threshold
Novo Nordisk Reports Positive Phase 3 STEP Young Results for Semaglutide in Children With Obesity Novo Nordisk has announced the first results from the STEP Young Phase 3 trial evaluating…
Scholar Rock Announces FDA Approval of ISEMBYLD™ for Spinal Muscular Atrophy
Scholar Rock Wins FDA Approval for ISEMBYLD, First Muscle-Targeted Treatment for Spinal Muscular Atrophy Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company focused on developing therapies for rare, severe and…
Strata Mental Health Receives Compass Pathways Grant for COMP360 Provider Training
Strata Mental Health Solutions Awarded Compass Pathways Grant to Develop U.S. Provider Training for COMP360 Strata Mental Health Solutions, an expert-led training and implementation partner focused on preparing clinical networks…
MEDIPAL and JCR Pharmaceuticals Dose First Patient in Phase 1/2 Trial of JR-446 for MPS IIIB
MEDIPAL and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for MPS IIIB MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Co., Ltd. (TSE: 4552) announced that the…
Aptar Pharma Expands Preservative-Free Technology Production in Latin America
Aptar Pharma Transfers Advanced Preservative-Free Production Line to Argentina, Expanding Local Drug Delivery Manufacturing Aptar Pharma, a global provider of drug delivery, dosing, protection technologies and related services, has announced…
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Gossamer Bio Completes 1-for-80 Reverse Stock Split to Support Nasdaq Listing Compliance Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary arterial…
Bausch + Lomb Receives European CE Mark for SeeLyra™ Femtosecond Laser
Bausch + Lomb Receives European CE Mark for Next-Generation SeeLyra Femtosecond Laser Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global eye health company focused on helping people see better and…
Nutromics Receives FDA Breakthrough Device Designation
Nutromics Receives FDA Breakthrough Device Designation for Wearable Vancomycin Monitoring Patch Nutromics, a medical technology company developing a wearable lab-on-a-patch™ platform for continuous molecular monitoring, announced that the U.S. Food…
One Biosciences Secures €3.3M France 2030 Funding for Breast Cancer Diagnostic
One Biosciences and Institut Curie Secure €3.3 Million France 2030 Funding to Advance Single-Cell Diagnostics for Triple-Negative Breast Cancer One Biosciences, a techbio company spun out of Institut Curie and…
Exegenesis Bio and Modalis Collaborate to Advance MDL-201 for Duchenne Muscular Dystrophy
Exegenesis Bio and Modalis Partner to Advance MDL-201 Gene Therapy for Duchenne Muscular Dystrophy Exegenesis Bio and Modalis Therapeutics Corporation (TOKYO: 4883) have entered into a research collaboration and license…